Literature DB >> 620951

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.

J H Edmonson, D G Decker, G D Malkasian, M J Webb, E O Jorgensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 620951     DOI： 10.1016/0090-8258(78)90002-1

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  6 in total

Review 1.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 2.  Oral etoposide for the treatment of recurrent ovarian cancer.

Authors:  R F Ozols
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 3.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.

Authors:  M Markman; T Hakes; B Reichman; J Curtin; R Barakat; S Rubin; W Jones; J L Lewis; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 5.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.